Value of mesenchymal stem cell therapy for patients with septic shock: an early health economic evaluation.
Walter P WodchisSasha van KatwykMurray KrahnShirley H J MeiDuncan J StewartDean FergussonDoug CoyleLauralyn McIntyrePublished in: International journal of technology assessment in health care (2020)
At a common WTP of $50,000/QALY, MSC therapy is deemed to be economically attractive if its unit cost does not exceed $16,748. This ceiling price can be increased to $101,450 if the therapy significantly reduces both in-hospital mortality and increases hospital discharge rates.